By Dr Charles Edo de Bock

Conference Abstracts

Govaerts I; Gielen O; Habets R; de Bock C; De Keersmaecker K; Segers H; Uyttebroeck A; Maertens J; Boeckx N; De Strooper B; Cools J, 2019, 'PF159 COMBINATION OF SELECTIVE GAMMA‐SECRETASE INHIBITOR MRK‐560 WITH OTHER TARGETED THERAPY IS AN EFFECTIVE AND SAFE TREATMENT FOR T‐ALL', in HemaSphere, Wiley, Vol. 3, pp. 31 - 31, http://dx.doi.org/10.1097/01.hs9.0000558852.50584.54

Verbeke D; de Bock C; Demeyer S; Prieto C; De Bie J; Gielen O; Mentens N; Daelemans D; Uyttebroeck A; Boeckx N; De Keersmaecker K; maertens J; Segers H; Cools J, 2019, 'PF165 THE XPO1 INHIBITOR KPT‐8602 WORKS SYNERGISTIC WITH DEXAMETHASONE TO INHIBIT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS', in HemaSphere, Wiley, Vol. 3, pp. 34 - 35, http://dx.doi.org/10.1097/01.hs9.0000558876.81078.b9

Van Thillo Q; De Bie J; Demeyer S; Tam WL; Sweron B; Geerdens E; Gielen O; Segers H; Boeckx N; Uyttebroeck A; Cools J; de Bock CE, 2019, 'PS916 TCF7-SPI1 AND NRAS (G12D) COOPERATE IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HemaSphere, Wiley, Vol. 3, pp. 413 - 413, http://dx.doi.org/10.1097/01.hs9.0000561944.30888.3a

de Bock C; Habets R; Serneels L; Lodewijckx I; Verbeke D; Nittner D; Narlawar R; Demeyer S; Dooley J; Liston A; Taghon T; de Strooper B; Cools J, 2019, 'PS917 SAFE TARGETING OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUBUNIT SELECTIVE GAMMA-SECRETASE INHIBITION', in HemaSphere, Wiley, Vol. 3, pp. 413 - 414, http://dx.doi.org/10.1097/01.hs9.0000561948.38512.48

Loontiens S; Durinck K; Vanhauwaert S; Depestel L; Oliveira ML; Dewyn G; de Bock C; Barata JT; Langenau D; Cools J; Taghon T; Van Vlierberghe P; Speleman F, 2019, 'PS920 PHF6 LOSS DRIVES IL7R ONCOGENE ADDICTION IN TLX1 DRIVEN T‐ALL', in HemaSphere, Wiley, Vol. 3, pp. 414 - 415, http://dx.doi.org/10.1097/01.hs9.0000561956.76629.c7

Broux M; Prieto C; Demeyer S; Vanden Bempt M; Alberti‐Servera L; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J, 2019, 'S858 SUZ12 INACTIVATION COOPERATES WITH JAK3 MUTANT SIGNALING TO DRIVE T‐ALL DEVELOPMENT', in HemaSphere, Wiley, Vol. 3, pp. 383 - 384, http://dx.doi.org/10.1097/01.hs9.0000561712.29231.fb

Working Papers

Omari SA; Geraghty DP; Khalafallah AA; Venkat P; Shegog YM; Ragg SJ; de Bock CE; Adams MJ, 2021, Optimized Flow Cytometric Detection of Transient Receptor Potential Vanilloid-1 (TRPV1) in Human Hematological Malignancies, medRxiv, http://dx.doi.org10.1101/2021.08.04.21261521

Preprints

Jing D; Beck D; Cao H; Tian F; Huang Y; Zhao H; Tai X; XU WENQIAN; Kosasih H; Kealy D; Bridge K; Zhao W; Holding A; Dowle A; Taylor S; Song G; Fajardo D; Walia Y; Wang M; Zhang C; Wang J; Mi J-Q; Lock R; de Bock C, 2024, PU.1 Eviction at Lymphocyte-Specific Chromatin Domains Mediates Glucocorticoid Response in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.21203/rs.3.rs-3872306/v1

Zhang Q; Li MK; Hu XY; Wang YY; Zhao PP; Cheng LN; Yu RH; Zhang XD; Chen S; Zhu ZM; de Bock C; Thorne R, 2023, The tumour suppressor Fat1 is dispensable for normal murine hematopoiesis, http://dx.doi.org/10.1101/2023.12.20.572284

Germon Z; Sillar J; Mannan A; Duchatel R; Staudt D; Murray H; Findlay I; Jackson E; McEwen H; Douglas A; McLachlan T; Schjenken J; Skerrett-Bryne D; Huang H; Melo-Braga M; Plank M; Alvaro F; Chamberlain J; Iuliis GD; Aitken J; Nixon B; Wei A; Enjeti A; Lock R; Larsen M; Lee H; de Bock C; Verrills N; Dun M, 2022, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687

Other

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Data from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.c.6529397

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Data from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.c.6529397.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplement from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476449

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplement from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476449.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 1 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476443

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 1 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476443.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 2 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476440.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 2 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476440

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 3 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476437

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 3 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476437.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476434.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476434

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476431

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476431.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 5 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476428.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 5 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476428

Barz CS; Benford ME; Mishra MK; Chia TS; Cooper E; Newton K; Bonel N; de Bock C; Farenhem K; Zupanc J; Elsanadidy E; Gopinath SD; Winter M; Kemp KC; Nieuwenhuis R; Hoyer JS; Li R; Lindsay G; Li D; O'Mullane A; Schuenemann KC; Ramirez D; Yu SS; Pun M; Li CY, 2016, Measures of success, AMER ASSOC ADVANCEMENT SCIENCE, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373039600017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Bock C, 2016, Measures of success Reply, AMER ASSOC ADVANCEMENT SCIENCE, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373039600052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page